Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized observer-blind study of AS03-adjuvanted monovalent H5N1 influenza vaccine in adults
2006-001281-16Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) in Influenza A infection (2 arms), sponsored by GSK. Primary endpoints: Safety and reactogenicity and Humoral immunogenicity at 21 days after each vaccination. Started Mar 2006; status: completed.
02
Drugs
prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2006-001281-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001281-16.